INTRODUCTION
H IV-1 GENE EXPRESSION is dependent on the association of HIV-1 Tat with the transactivation response element (TAR) in the nascent viral RNA. The process is assisted by the binding of several cellular proteins, such as cyclin T1 or cyclindependent kinase 9. [1] [2] [3] [4] [5] [6] [7] [8] As the interaction of HIV-1 Tat with TAR is unique to HIV-1, it provides an ideal target for pharmaceutical intervention. However, specific interference with any of the involved viral or cellular factors should inevitably result in the block of viral expression in the infected cell.
In vitro, a variety of compounds targeting HIV-1 transcription have been demonstrated to efficiently inhibit HIV-1 replication. Among these compounds are several inhibitors of the Tat-TAR interaction that bind to several sites in the TAR RNA. The multicyclic dyes, Hoechst 33258, DAPI, and berenil bind to the cavity created by the trinucleotide bulge. [9] [10] [11] [12] The Novartis compound CGP 40336A binds selectively to the AU base pair above the trinucleotide bulge with additional stacking interactions to the bulge. 13 Neomycin binds to the minor groove of the lower helix, whereas argininamide binds to the U23-A27-U38 base triple. [14] [15] [16] [17] [18] Other compounds inhibit HIV-1 transcription without interfering with Tat-TAR interaction (K-12, Ro24-7429), [19] [20] [21] but thus far, none of these have proven clinically useful. For example, in the case of the clinically tested HIV-1 Tat inhibitor Ro24-7429, 21 no inhibitory effect on HIV-1 replication in patients was observed during a phase 1/2 clinical trial, despite sufficiently high drug plasma levels and no development of viral resistance. 22 A common theme during the identification of previous HIV-1 transcription inhibitors in in vitro assays is the use of end point experiments that measure the cumulative effect of HIV-1 inhibition several days following de novo infection in the presence of the respective inhibitor. For an inhibitor to appear efficient in these types of assays, it is sufficient to substantially lower the initial infection. As the assays determine the level of cumulative infection several days after the initial infection, an initial difference in the infection level between treated and untreated cultures is exponentially amplified through the short generation time of HIV-1. Inhibition of de novo infection cannot be distinguished from inhibitory effects on established HIV-1 replication. As HIV-1 de novo infection is abolished by even minor compound toxicities, infectivity assays accordingly produce high levels of false-positive hits.
To increase the predictive value of experimental systems that measure the efficacy of inhibitors for the in vivo situation, it has been suggested that the inhibitory onset kinetics be determined rather than the cumulative outcome of inhibition. 23 In such assays, time-effect curves are generated by measuring cumulative inhibition at several time points. In the case of HIV-1 transcription inhibitors, the obtained curves would then allow for the calculation of the ability of a particular substance to suppress HIV-1 transcription immediately upon application.
Toward the development of such a system, we have established a chronically actively HIV-1-infected reporter T cell line, in which enhanced green fluorescence protein (eGFP) is a direct and quantitative marker of HIV-1 expression. Because at the time point of analysis the virus is already fully integrated, this cell line exclusively detects HIV-1 inhibitors that target HIV-1 transcription. To reliably distinguish between specific hits and false-positive hits caused by compound toxicities, which would also result in a decay of eGFP fluorescence, the cell line was further engineered to constitutively express a red fluorescence protein (RFP), which has no spectral overlap with eGFP. RFP is expressed under the control of the murine stem cell promoter, which, similar to promoters of "housekeeping genes" (e.g., GAPDH, actin), in our hands does not respond to activating stimuli (e.g., phorbol myristate acetate [PMA], tumor necrosis factor α [TNF-α]), an important characteristic to allow for normalization of the HIV-1-specific eGFP signal. Based on the detailed analysis of the effect of the established HIV-1 transcription inhibitor Ro24-7429 on HIV-1 expression in CUCY cells and peripheral blood mononuclear cells (PBMCs) and data from a 1000-compound proof-of-concept drug screen, we demonstrate the ability of the reporter cell line to be used for drug screening in a 384-well plate-based format.
MATERIAL AND METHODS

Cells and reagents
JLTRG cells have been described elsewhere. 24, 25 To obtain CUCY cells, JLTRG cells were infected with the primary dualtropic patient-isolate HIV-1 CUCY. The surviving chronically actively infected cells, as indicated by high eGFP expression, were cloned using the single-cell deposition unit of a FACStarPlus cell sorter (Beckton & Dickinson, San Diego, CA). CUCY cells were selected based on their high expression levels of eGFP. J89GFP cells and HIV-1 NLENG1 have been described elsewhere. 26 All cell lines were maintained in RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-inactivated fetal bovine serum. Preparation and infection of PBMCs has been described elsewhere. 26 Phytohemagglutinin-L (PHA-L) was obtained from Sigma (St. Louis, MO) and interleukin-2 was purchased from Biosource (Carlsbad, CA). Ro24-7429 was kindly provided by Hoffmann-LaRoche Inc. (Nutley, NJ). 3TC and indinavir were obtained from the National Institutes of Health AIDS Research and Reagent Program. The small-molecule chemical compound library used for the drug screen was purchased from ChemBridge Corporation (San Diego, CA).
Flow cytometric analysis of HIV-1 expression and cytotoxicity
CUCY cells were seeded at a density of 1 × 10 6 cells/ml in 24-well plates and then treated with Ro24-7429. eGFP expression was analyzed using a FACStar Plus flow cytometer (Becton & Dickinson). Dead cell exclusion was performed by the addition of propidium iodide (PI) and gating on PI-negative cells. Quantification of cytotoxicity levels for each individual sample was based on the ratio of PI-negative cells in the live gate to total counts using forward scatter (FSC)/side scatter (SSC) analysis. Data were analyzed using CellQuest software (Becton & Dickinson). The exact determination of the cellular proliferation rate of CUCY cells is required for the determination of the effective half-life of eGFP in this system. The effective half-life of eGFP represents the product of the physical half-life of the eGFP protein (τ1 2 = 24 h) and the inverse doubling rate of CUCY cells, which needs to be taken into account, as the eGFP content of an individual cell is decreased by 50% with each cell division. This is achieved through the addition of a defined amount of SPHERO blank calibration particles (diameter = 6-6.4 µm) to the cell cultures at the start of the experiment. The beads are easily distinguishable from the cells in the FSC/SSC during flow cytometric analysis. The ratio of beads to cells determined at various time points over a 120-h period then allows for the absolute or relative calculation of the proliferation rate.
Determination of cumulative fluorescence in a high-throughput drug screening-amenable plate-based format
To determine the feasibility of CUCY cells to be used in a high-throughput screening (HTS)-amenable format, the cells were seeded into 96-well or 384-well clear-bottom (low fluorescence) plates with black walls. The cell density was 9 × 10 5 cells per well in 200 µl phenol red-free RPMI 1640 medium for 96-well plates and 1 × 10 5 cells per well in 100 µl medium per well in 384-well plates. Quantification of cumulative fluorescence was performed using a BioTek (Winooski, VT) Synergy HT multidetection microplate reader optimized to read eGFP (excitation filter = 480/20 nm; emission = 525/20 nm).
Calculation
The coefficients of the mathematical equations describing the observed regulation of eGFP expression in the various experimental setups, which in turn allow us to draw conclusions about the inhibitory drug-onset kinetics, were determined using MacCurveFit 1.1.2 software. To model the observed curves that describe the increase and/or decrease of eGFP expression following drug application and/or addition of stimulating agents (e.g., TNF-α), it was generally assumed that drug uptake of Ro24-7429 was instantaneous. Calculation of the eGFP decay observed or modeled in Figure 2A was based on an evasion kinetic of the 1st order (c t = c 0 exp(-k e t)), with c t being the relative concentration of eGFP expression at the time point t, c 0 being the eGFP concentration at the beginning of the experiment (t = 0), and the evasion coefficient being k e [t -1 ]. The curve in Figure 2B that describes the influence of Ro24-7429 on the kinetic and expression level of TNF-α mediated HIV-1 reactivation in J89GFP cells is best described by a Bateman function (c t = c 0 (k i /(k i -k e ))(exp(-k e t) -exp(-k i t)); (k e : evasion coefficient; k i : invasion coefficient). The curve representing the observed changes in eGFP fluorescence intensity in J89GFP cells as a result of TNF-α stimulation in the absence of the inhibitor can be described by an invasion kinetic of the 1st order (c t = 1 -(c 0 exp(-k i t)). In each case, the coefficients were determined by the quasi-Newton method, which uses the David-Fletcher-Powell algorithm. 27 The quality of the curve fit was assessed by the correlation coefficient R 2 .
RESULTS
Single-cell analysis of the inhibitory onset kinetics of the HIV-1 transcription inhibitor Ro24-7429
To directly determine the inhibitory onset kinetics of a putative HIV-1 transcription inhibitor, we developed a reporter T cell line (CUCY cells; see the "Material and Methods" section), in which eGFP fluorescence serves as a direct and quantitative marker of HIV-1 expression that indicates the presence of HIV-1 transcription inhibitors (Fig. 1A) . CUCY cells can be conveniently used for kinetic analysis of HIV-1 expression following application of a 1-time dose of an HIV-1 transcription inhibitor. Addition of the established HIV-1 transcription inhibitor Ro24-7429 results in a dose-dependent gradual decline of the observed eGFP fluorescence levels, with maximum inhibition being observed on day 8 (Fig. 1B) . The tight correlation of eGFP fluorescence and HIV-1 protein expression in CUCY cells can be demonstrated by the comparison of HIV-1 p24 expression and eGFP fluorescence following addition of various concentrations of the HIV-1 transcription inhibitor Ro24-7429 ( Fig. 1B, C) . In addition, it is also possible to study how continuous addition of an HIV-1 transcription inhibitor (here Ro24-7429) over an extended period abrogates HIV-1 expression ( Fig. 1D) .
Determination of inhibitory onset kinetics
As HIV-1/eGFP expression levels in CUCY cells can be determined in a noninvasive manner, CUCY cells allow for the convenient and direct quantification of the inhibitory onset kinetics, as well as for the study of the cumulative outcome of inhibition several days after the introduction of a test compound. By repeatedly measuring eGFP expression levels over the course of an experiment using a plate-based fluorometer, we determined cumulative outcome of inhibition as well as the inhibitory onset kinetics of an established HIV-1 transcription inhibitor (Ro24-7429). Complete and instantaneous inhibition of HIV-1 or eGFP expression, respectively, can be modeled as an exponential decay based on the effective half-life of eGFP in CUCY cells (τ1 2 = 0.5 d). In this model, a complete transcription block results in almost complete eGFP inhibition after 3 days ( Fig. 2A, squares) . In contrast, the observed Ro24-7429-mediated inhibition of HIV-1 expression was characterized by an extended eGFP half-life of τ1 2 = 2.4 d (57.6 h), and maximum inhibition was achieved only 8 days after Ro24-7429 treatment, when eGFP fluorescence was reduced to 10% of the GFP expression seen in untreated control cells ( Fig. 2A, circles) .
As the half-life of some short-lived viral proteins is approximately similar to the half-life of eGFP in this system, the amount of virus produced over a defined period of time can be directly determined by integration of the equations describing the different curves. The relative virus amounts produced under the different conditions as obtained by integration are equal to the surface of the area under the respective curve over the period of interest ( Fig. 2A) . Here, the calculation was performed for a 2-day time period, which was chosen based on the short in vivo lifespan of HIV-1-infected T cells (τ1 2 ≤ 1.2 d), 28, 29 during which Tat inhibitors need to achieve full inhibition of HIV-1 expression to prove efficient. Area C (Fig. 2) , under the modeled eGFP decay following instantaneous and complete inhibition of HIV-1/eGFP expression, represents the inertia of the system that is caused by the relatively slow physical decay of eGFP and has to be excluded from the calculation. The experiments reveal that Ro24-7429-treated CUCY cells still produce 70% of the virus load of untreated cells during the initial 2-day period ( Fig. 2A) . Over a period of 4 days, total virus production in the presence of Ro24-7429 would be reduced to 40%. Determination of cumulative outcome on day 6, however, would predict that at least 80% of viral replication would be inhibited.
As HIV-1 infection in its majority takes place in highly activated environments such as the lymph nodes, HIV-1 transcription inhibitors must be potent enough to suppress HIV-1 transcription despite the presence of activating cytokines. To evaluate the potency of a compound to inhibit HIV-1 transcription in an activated environment, we have developed a 2nd assay based on several latently HIV-1-infected reporter cell lines. In the presented experiments, the latently HIV-1-infected reporter T cell line J89GFP 26 was pretreated with Ro24-7429 and then stimulated with 1 ng/ml TNF-α. As reactivation of latent HIV-1 is dependent on Tat activity, a sufficiently potent Tat inhibitor should suppress HIV-1 reactivation and, as such, eGFP fluorescence. In Figure 2B , we demonstrate that the established HIV-1 transcription inhibitor Ro24-7429 is not capable of suppressing reactivation of latent HIV-1 infection in J89GFP cells triggered by the addition of TNF-α. In this setting, over the initial 2-day period, Ro24-7429 suppressed only 20% of the HIV-1 expression. Taken together, these data suggest that data obtained for cumulative outcome of inhibition would predict a higher level of in vivo drug efficacy for Ro24-7429 than suggested by the kinetic inhibitory onset data obtained for the same compound.
Influence of Ro24-7429 on HIV-1 replication in immortalized T cells and PBMCs
We next addressed the question as to whether this difference between cumulative outcome and inhibitory onset kinetics as predictors of drug efficacy could also be found in HIV-1 infectivity assays. For this purpose, we infected PBMCs with an eGFP reporter virus and monitored replication kinetics by flow cytometric analysis. Four days postinfection, a single dose of the HIV-1 transcription inhibitor Ro24-7429 was added at various concentrations, and HIV-1 replication was followed over an additional period of 7 days (Fig. 3A) . During this 7-day period, an average 75% decrease in the percentage of the HIV-1-infected cells was observed in the control culture, probably induced by the cytotoxic effect of the virus (Fig. 3A) , whereas overall cell viability was not significantly decreased, as the infection reaches only 5% to 8% of all cells. Within the initial first 2 days of the culture, we observed only a 12% reduction in the level of infected cells that was attributable to Ro24-7429. The maximum inhibitory effect attributable to Ro24-7429 was achieved on day 5 at a concentration of 10 µM, when an additional 25% reduction of the level of HIV-1 infection could be observed. At 30 µM, the compound decreased HIV-1 replication by 40%; however, a distinct cytotoxic effect of the compound became apparent at this concentration (data not shown). After day 5, the level of HIV-1 infection in the Ro24-7429-treated PBMCs increased again, indicating that Ro24-7429 had only delayed expression of HIV-1.
Drug screening for HIV-1 transcription inhibitors based on the CUCY cell system
After we had confirmed that the quantitative kinetic results obtained during experiments using the reporter cell line were consistent with kinetic results that can be obtained using infectivity assays, we proceeded to test the feasibility of the reporter system to be used in an HTS-compatible plate-based format. The ability of a cell-based reporter system to be used in a platebased format amenable to high-throughput screening can be best evaluated by performing a Z′ test. The experimentally determined Z′ factor is a statistic value designed to reflect the dynamic range of the assay as well as the variation associated with the signal measurements. 30 The equation and the meaning of possible Z′ factor values are summarized in equation 1. As we have previously demonstrated, maximum achievable eGFP/HIV-1 inhibition results in the same level of eGFP fluorescence as stimulation of the parental, non-HIV-1-infected JLTRG cells with TNF-α or PMA (Fig. 1) . We thus initially determined the theoretically achievable Z′ factor by partitioning a 384-well plate in quadrants that were then manually loaded with either 1 × 10 5 CUCY cells or 1 × 10 5 TNF-α-stimulated JLTRG cells per well. The determined Z′ factor had a value of 0.95, indicating a very robust assay (Fig. 4A) . We then used a similar experimental setup to test whether kinetic analysis of Ro24-7429-mediated inhibition of HIV-1 expression determining eGFP bulk fluorescence by a fluorescence plate reader or single cell analysis using flow cytometry would reveal similar results. For this purpose, we loaded a 96-well section of a 384-well plate with CUCY cells and treated two 24-well quadrants with Ro24-7429. In this setting, eGFP fluorescence in the first 24 h remained unaltered by the presence of Ro24-7429 and then, until day 4, gradually declined to 33% of the eGFP expression level detected in untreated CUCY cells. The Z′ factor determined under these experimental conditions was 0.9. These data correlate very well with data obtained by flow cytometric analysis, in which eGFP mean channel fluorescence by day 4 had decreased to 22% of the original fluorescence intensity (Fig. 1) , demonstrating the feasibility of the reporter system to screen for HIV-1 Tat inhibitors in a 384-well format.
HTS for HIV-1 Transcription Inhibitors
Proof-of-concept drug screen
To proof the reliability of the reporter system and to determine its resolution, we performed a proof-of-concept drug screen. For this purpose, compounds from a commercially available compound library were loaded at a final average concentration of 3 µM into 384-well plates, and CUCY cells (1 × 10 5 per well) were added. Immediately after manual loading of the plates, an initial screen was performed to detect potential compound autofluorescence. Of the compounds, 1.3% had to be excluded from the screen because of autofluorescent characteristics. eGFP and RFP fluorescence intensity was then determined at the 1-, 2-, 3-, 4-, and 7-day time point. By this means, we were able to measure the initial decay rate of the eGFP signal as well as the cumulative outcome of HIV-1/ GFP inhibition after 7 days. Similarly, determination of the kinetic RFP profile allowed for the determination of toxic drug effects with high resolution. Figure 5 depicts the eGFP and RFP fluorescence intensity data for a randomly chosen set of 2 × 384 wells as obtained on days 2, 4, and 7 following drug addition. As expected, the limited proof-of-concept screen identified a significant number of hits based on the sole employment of eGFP as a marker of HIV-1 expression (66 hits or 6.9% hit rate). Following inclusion of the RFP-based toxicity marker, all initially detected hit compounds were identified as false-positive hits, which demonstrates the efficacy of the eGFP/RFP marker combination to successfully identify falsepositive hits. Although only a few compounds caused detectable levels of cytotoxicity on day 2, toxic effects were clearly visible on days 4 and 7. The high overall correlation of the decrease in RFP and eGFP fluorescence intensity throughout the entire sample set (day 4: R 2 = 0.68; day 7: R 2 = 0.83) demonstrates the ability of the RFP marker to reliably identify false-positive hits. A larger, 3200-compound data set analyzed for cumulative outcome of inhibition at the day 7 time point is presented in Figure 6 . The screen reliably detected known inhibitors of HIV-1 transcription, such as Ro24-7249 and WP631, 24 that were used as positive controls. In addition, 4 compounds that have very high structural similarity with temacrazine, an HIV-1 transcription inhibitor described previously, were identified. 31
DISCUSSION
Cell-based HTS for HIV-1 inhibitors has largely been abandoned, as standard infectivity assays are hampered by the high rate of false-positive hits induced by even minor compound toxicities and the lack of specificity for a defined viral target. By designing a highly efficient T cell-based drug-screening system that specifically identifies HIV-1 transcription inhibitors and simultaneously discriminates against compounds with cytotoxic effects, we demonstrate that it is possible to overcome the limitations of HIV-1 infectivity assays. In the presented assay, HIV-1 inhibitory capacity and potential toxicity of a drug are indicated by changes in the fluorescence intensity of 2 fluorescent proteins that exhibit no spectral overlap. With both fluorescent markers for HIV-1 inhibition and drug cytotoxicity being stably integrated into the reporter cell line, drug screening is extremely efficient, as the system requires no manipulation during assay preparation and analysis.
An HTS system should be highly specific for a particular target, produce low levels of false-positive hits, and be cost-efficient when used in a large-scale drug screen. To realize these goals for a cell-based HTS assay for HIV-1 transcription inhibitors, we established a chronically active HIV-1-infected reporter T cell line in which inhibition of HIV-1 transcription is indicated by a decrease in eGFP fluorescence intensity. Because the energydependent steps prior to HIV-1 gene expression (from entry to integration) and not HIV-1 promoter controlled gene expression are extremely susceptible to minor compound toxicities, a chronically infected reporter cell line is relatively resistant against the regulatory influence of minor compound toxicities. By this means, a major complication of infectivity assays could be eliminated, but more important, a decrease in the eGFP signal will exclusively indicate compounds that interfere with HIV-1 transcription. Inhibitors that target preintegration steps (entry/fusion, reverse transcription, integration) or postexpression steps (e.g., protease cleavage, assembly) will not be detected, providing utmost target specificity, similar to molecular screening assays. To further improve the ability of the assay to exclude false-positive hits, a major factor for costefficient lead compound identification and subsequent drug development, we included a toxicity marker that is simultaneously accessible with the HIV-1-specific eGFP marker, eliminating the time-consuming and costly requirement for a separate toxicity screen. For this purpose, CUCY cells were retrovirally transduced with a 2nd RFP that exhibits no spectral overlap with eGFP and can be efficiently detected on a plate-based fluorescent reader. RFP is expressed under the control of the murine stem cell virus promoter, which expresses unvarying levels of RFP, independent of the cellular activation state. This characteristic is a prerequisite to allow for the normalization of changes in the eGFP level. The efficiency of the combined utilization of the 2 markers becomes obvious in the presented 1000-compound proof-of-concept drug screen. Although the HIV-1-specific eGFP marker by itself would have suggested that 6.8% of the screened compounds would be HIV-1 transcription inhibitors, inclusion of the RFP-based toxicity marker revealed that these were exclusively false-positive hits. The drug screen also reveals the extent of the major weakness of an HTS system based on fluorescent proteins as readout. Of the compounds, 1.3% had to be eliminated from the screen because of autofluorescent characteristics. It is, however, possible to selectively remove these cells from their wells and subject them to flow cytometric analysis. We have found in other extended screening efforts that most of the autofluorescent compounds do not stain the cells and thus remain amenable to single-cell analysis of the eGFP and RFP marker (data not shown). When run in a 384-well plate-based format, the reporter assay is characterized by a Z′ factor of 0.9. The high reliability of the assay demonstrated in the limited drug screen, combined with the fact that the assay requires no manipulations during assay development or analysis (e.g., transfection of reporter plasmids, cell lysis, transfer of supernatants, addition of chemicals), renders the assay ideal for large-scale screening efforts. In addition to the convenience of direct and manipulationfree signal quantification, the use of fluorescent proteins as markers has an additional advantage. As changes in the fluorescence intensity can be continuously monitored without interference with the ongoing cell culture, this is the 1st system that allows not only for the measurement of cumulative outcome of inhibition but also for the direct determination of the inhibitory onset kinetics of a compound. 23 The data generated for cumulative outcome of inhibition and the determination of the inhibitory onset kinetics using the established HIV-1 transcription inhibitor Ro24-7429 would indeed suggest that these predictors of drug efficacy may produce conflicting results. Addition of Ro24-7429 to CUCY cells resulted in a cumulative inhibition of HIV-1 expression on days 4 to 8, similar to results that have been previously published (80%-90% inhibition). 21 However, when we quantified instantaneous inhibition as measured by the decrease of eGFP expression over the initial first 2 days, it became obvious that Ro24-7429 had very slow inhibitory onset kinetics, reducing virus output during the first 2 days by only 30%. As the average productively HIV-1-infected T cell in vivo has a life span of only 2 to 3 days, 21 it is tempting to speculate whether the slow inhibitory onset kinetics of the Ro24-7429 compound were part of the clinical failure of the drug. 21 Determining the inhibitory drug efficacy by measuring the inhibitory onset kinetics of an HIV-1 transcription inhibitor may be more predictive for the ability of a compound to inhibit HIV-1 replication in vivo than results obtained by determining the cumulative outcome of inhibition at a later time point. As currently no clinically efficient HIV-1 transcription inhibitors are available, this statement remains speculative. It is noteworthy, though, that the inhibitory onset kinetics observed for Ro24-7429 in the CUCY systems were paralleled by the course of viral replication in PBMCs monitored at the single-cell level.
It is obvious that the combination of kinetic and cumulative outcome data obtained during a drug screen using CUCY cells will allow for an improved evaluation of the inhibitory efficacy of potential hits and will assist the decision to transfer an optimized selection of initial hits to the drug evaluation phase. The compounds with the fastest inhibitory onset kinetics and the highest inhibitory amplitude should be transferred to this phase, provided they exhibit a sufficiently druglike structure. It will be interesting to see whether, in the absence of an efficient nontoxic inhibitor of a Tat/TAR interaction (strictly speculative), the kinetic inhibitory pattern of an HIV-1 transcription inhibitor that interferes with cellular factors can be efficiently distinguished from the inhibitory kinetic footprint of a Tat/TAR inhibitor.
In summary, the reporter system quantitatively reflects findings that can be made in HIV-1-infected PBMC cultures, in which HIV-1 replication is determined at the single-cell level. Because the reporter system in a 384-well plate-based format simultaneously provides data on the inhibitory onset kinetics, the amplitude of inhibition, and the cytotoxicity of a compound, it should greatly facilitate future large-scale drug screens for novel HIV-1 transcription inhibitors.
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